Multicenter analysis of neutrophil extracellular trap dysregulation in adult and pediatric COVID-19.
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
03 Mar 2022
03 Mar 2022
Historique:
entrez:
9
3
2022
pubmed:
10
3
2022
medline:
10
3
2022
Statut:
epublish
Résumé
Dysregulation in neutrophil extracellular trap (NET) formation and degradation may play a role in the pathogenesis and severity of COVID-19; however, its role in the pediatric manifestations of this disease including MIS-C and chilblain-like lesions (CLL), otherwise known as "COVID toes", remains unclear. Studying multinational cohorts, we found that, in CLL, NETs were significantly increased in serum and skin. There was geographic variability in the prevalence of increased NETs in MIS-C, in association with disease severity. MIS-C and CLL serum samples displayed decreased NET degradation ability, in association with C1q and G-actin or anti-NET antibodies, respectively, but not with genetic variants of DNases. In adult COVID-19, persistent elevations in NETs post-disease diagnosis were detected but did not occur in asymptomatic infection. COVID-19-affected adults displayed significant prevalence of impaired NET degradation, in association with anti-DNase1L3, G-actin, and specific disease manifestations, but not with genetic variants of DNases. NETs were detected in many organs of adult patients who died from COVID-19 complications. Infection with the Omicron variant was associated with decreased levels of NETs when compared to other SARS-CoV-2 strains. These data support a role for NETs in the pathogenesis and severity of COVID-19 in pediatric and adult patients. NET formation and degradation are dysregulated in pediatric and symptomatic adult patients with various complications of COVID-19, in association with disease severity. NET degradation impairments are multifactorial and associated with natural inhibitors of DNase 1, G-actin and anti-DNase1L3 and anti-NET antibodies. Infection with the Omicron variant is associated with decreased levels of NETs when compared to other SARS-CoV-2 strains.
Identifiants
pubmed: 35262093
doi: 10.1101/2022.02.24.22271475
pmc: PMC8902885
pii:
doi:
Types de publication
Preprint
Langues
eng
Commentaires et corrections
Type : UpdateIn
Références
Nature. 2021 Dec;600(7887):21
pubmed: 34824381
J Allergy Clin Immunol. 2021 Jan;147(1):57-59
pubmed: 33075409
Blood. 2020 Sep 3;136(10):1169-1179
pubmed: 32597954
Mediators Inflamm. 2020 Dec 2;2020:8829674
pubmed: 33343232
Nat Rev Immunol. 2020 Aug;20(8):453-454
pubmed: 32546853
Nat Genet. 2001 Aug;28(4):313-4
pubmed: 11479590
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620938149
pubmed: 32677459
Crit Rev Clin Lab Sci. 2021 Aug;58(5):297-310
pubmed: 33347790
Lancet Microbe. 2020 Nov;1(7):e290-e299
pubmed: 33015653
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32302401
JCI Insight. 2017 Feb 9;2(3):e89780
pubmed: 28194438
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Proc Natl Acad Sci U S A. 2010 May 25;107(21):9813-8
pubmed: 20439745
Blood Adv. 2020 Dec 8;4(23):6051-6063
pubmed: 33290544
J Exp Med. 2020 Dec 7;217(12):
pubmed: 32926097
Nature. 2021 May 5;:
pubmed: 32221507
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643232
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Nat Rev Genet. 2021 Dec;22(12):757-773
pubmed: 34535792
J Cutan Pathol. 2022 Jan;49(1):17-28
pubmed: 34272741
J Exp Med. 2020 Dec 7;217(12):
pubmed: 32926098
JAMA Dermatol. 2021 Aug 1;157(8):947-953
pubmed: 34160569
Cell. 2020 Nov 12;183(4):968-981.e7
pubmed: 32966765
Life Sci. 2020 Nov 1;260:118431
pubmed: 32946915
JCI Insight. 2021 Aug 9;6(15):
pubmed: 34166229
J Med Virol. 2021 Jan;93(1):250-256
pubmed: 32592501
J Thromb Thrombolysis. 2021 Feb;51(2):446-453
pubmed: 33151461
Vascul Pharmacol. 2021 Apr;137:106829
pubmed: 33422689
Science. 2004 Mar 5;303(5663):1532-5
pubmed: 15001782
Neurobiol Dis. 2021 Dec;161:105561
pubmed: 34780863
Science. 2022 Feb 18;375(6582):760-764
pubmed: 35050643
Semin Oncol. 2020 Oct;47(5):330-334
pubmed: 32736881
Front Immunol. 2012 Dec 14;3:380
pubmed: 23248629
JAMA Dermatol. 2021 Feb 1;157(2):202-206
pubmed: 33237291
J Clin Invest. 2020 Nov 2;130(11):6151-6157
pubmed: 32759504
Allergy. 2020 Jul;75(7):1564-1581
pubmed: 32396996
J Immunol. 2012 Apr 1;188(7):3522-31
pubmed: 22345666
JAMA Dermatol. 2020 Sep 1;156(9):1003
pubmed: 32584385
Ann Rheum Dis. 2015 Jul;74(7):1417-24
pubmed: 24570026
Br J Dermatol. 2021 Dec;185(6):1176-1185
pubmed: 34611893
Eur J Haematol. 2020 Nov;105(5):540-546
pubmed: 32663356
J Exp Med. 2021 May 3;218(5):
pubmed: 33783474
Nat Med. 2020 Nov;26(11):1701-1707
pubmed: 32812012
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Int J Infect Dis. 2020 Oct;99:276-278
pubmed: 32763444
J Am Acad Dermatol. 2020 Sep;83(3):870-875
pubmed: 32502585
Pediatr Dermatol. 2020 May;37(3):406-411
pubmed: 32386460
Lancet. 2022 Jan 29;399(10323):412-413
pubmed: 35065007
JCI Insight. 2020 Jun 4;5(11):
pubmed: 32329756
Br J Dermatol. 2020 Oct;183(4):729-737
pubmed: 32562567
J Infect Public Health. 2020 Dec;13(12):1833-1839
pubmed: 32788073
Int J Infect Dis. 2021 Jan;102:53-55
pubmed: 33075530
EBioMedicine. 2020 Aug;58:102925
pubmed: 32745993
Ageing Res Rev. 2021 Jan;65:101205
pubmed: 33137510
Cytokine Growth Factor Rev. 2020 Aug;54:62-75
pubmed: 32513566
Children (Basel). 2020 Jul 01;7(7):
pubmed: 32630212
Nat Med. 2021 May;27(5):892-903
pubmed: 33767405
FEBS J. 2020 Sep;287(17):3633-3650
pubmed: 32446285